{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:14:07Z","timestamp":1789110847127,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00868-3","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:36:48Z","timestamp":1777887408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study"],"prefix":"10.1186","volume":"24","author":[{"given":"Juan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-1472","authenticated-orcid":false,"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"8","key":"868_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):542\u20136.","journal-title":"Ann Intern Med"},{"key":"868_CR2","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1\u2013158.","DOI":"10.1111\/hae.14046"},{"issue":"1","key":"868_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","volume":"232","author":"IM NILSSON","year":"1992","unstructured":"NILSSON IM, BERNTORP E, L\u00d6FQVIST T. Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25\u201332.","journal-title":"J Intern Med"},{"issue":"5","key":"868_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16704","volume":"190","author":"R Rayment","year":"2020","unstructured":"Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020;190(5):684\u201395.","journal-title":"Br J Haematol"},{"issue":"77","key":"868_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","volume":"Suppl","author":"A Ahlberg","year":"1965","unstructured":"Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965;Suppl(77):3\u2013132.","journal-title":"Acta Orthop Scand Suppl"},{"issue":"2","key":"868_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rth2.12686","volume":"6","author":"K Huang","year":"2022","unstructured":"Huang K, Zhen Y, Li G, Wu X, Chen Z, Wu R. Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates. Res Pract Thromb Haemost. 2022;6(2):1\u20139.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"868_CR7","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1111\/hae.14336","volume":"27","author":"K Huang","year":"2021","unstructured":"Huang K, Zhen Y, Li G, Wu X, Chen Z, Wu R. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia. 2021;27(4):e450\u20137.","journal-title":"Haemophilia"},{"issue":"December 2021","key":"868_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2022.03.008","volume":"213","author":"K Huang","year":"2022","unstructured":"Huang K, Wang Y, Zhen Y, et al. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A. Thromb Res. 2022;213(December 2021):71\u20137.","journal-title":"Thromb Res"},{"issue":"4","key":"868_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/hae.14002","volume":"26","author":"D Pollard","year":"2020","unstructured":"Pollard D, Harrison C, Dodgson S, Holland M, Khair K. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia. 2020;26(4):622\u201330.","journal-title":"Haemophilia"},{"issue":"2","key":"868_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","volume":"22","author":"Y Teranishi-Ikawa","year":"2024","unstructured":"Teranishi-Ikawa Y, Soeda T, Koga H, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. J Thromb Haemost. 2024;22(2):430\u201340.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"868_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018;379(9):811\u201322.","journal-title":"N Engl J Med"},{"key":"868_CR12","doi-asserted-by":"crossref","unstructured":"Mao Q, Chen Z, Liu G, et al. Real-world use of Emicizumab in Chinese children with hemophilia a: retrospective data from a comprehensive care center. Pediatr Investig. 2024:244\u201352.","DOI":"10.1002\/ped4.12439"},{"issue":"3","key":"868_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/hae.14785","volume":"29","author":"S Bansal","year":"2023","unstructured":"Bansal S, Donners AAMT, Fischer K, et al. Low dose Emicizumab prophylaxis in haemophilia a patients: A pilot study from India. Haemophilia. 2023;29(3):931\u20134.","journal-title":"Haemophilia"},{"key":"868_CR14","doi-asserted-by":"crossref","unstructured":"Ye J, Huang K. From pharmacokinetic-guided FVIII prophylaxis to low-dose Emicizumab prophylaxis: a pilot study revealed a flush of hope. 2025:6013\u201320.","DOI":"10.1007\/s00277-025-06723-1"},{"issue":"16","key":"868_CR15","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","volume":"137","author":"MU Callaghan","year":"2021","unstructured":"Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with Emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies. Blood. 2021;137(16):2231\u201342.","journal-title":"Blood"},{"issue":"6","key":"868_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hae.13848","volume":"25","author":"M Shima","year":"2019","unstructured":"Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of Emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25(6):979\u201387.","journal-title":"Haemophilia"},{"issue":"24","key":"868_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of Emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127\u201338.","journal-title":"Blood"},{"key":"868_CR18","doi-asserted-by":"crossref","unstructured":"Kim SE, Kim JY, Park JA, et al. Real \u2013 world experience of Emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors. Blood Res. 2024:1\u20136.","DOI":"10.1007\/s44313-024-00039-1"},{"issue":"4","key":"868_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jtha.2023.12.023","volume":"22","author":"R Patil","year":"2024","unstructured":"Patil R, Shanmukhaiah C, Gogtay NJ, et al. Low-dose Emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients. J Thromb Haemost. 2024;22(4):1024\u201330.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"868_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hae.14707","volume":"29","author":"A Chuansumrit","year":"2023","unstructured":"Chuansumrit A, Sirachainan N, Jaovisidha S, et al. Effectiveness of monthly low dose Emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: A case series report. Haemophilia. 2023;29(1):382\u20135.","journal-title":"Haemophilia"},{"key":"868_CR21","doi-asserted-by":"crossref","unstructured":"Xu Y, Wang Y, Wu R, et al. Clinical haemophilia Reduced doses of Emicizumab achieve good efficacy: results from a national-wide multicentre real-world study in China. Haemophilia. 2024;(June 2023):959\u201369.","DOI":"10.1111\/hae.15062"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00868-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00868-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00868-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:16:05Z","timestamp":1782090965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00868-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00868-3","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of First Affiliated Hospital of Zhejiang University which also approved a consent waiver.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No AI used.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI use"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}